CELC/ 07/28/2025 · 10:03 AM Celcuity's Gedatolisib Shows Unprecedented Breast Cancer Trial Results Phase 3 VIKTORIA-1 trial shows gedatolisib triplet slashed disease progression risk by 76% in HR+/HER2- advanced breast cancer, with favorable safety.
